BioLineRx Sells APHEXDA Royalty Rights for $5.6M
The Israeli biotech company agreed to sell future royalty rights from its approved stem cell mobilization drug to Soleus Capital.
Updated on Nov. 18, 2026 in Biotech

BioLineRx has agreed to sell its rights to certain future APHEXDA royalties to Soleus Capital for $5.6 million. The sale covers the company's 14.4% royalty interest in future APHEXDA net sales, and the transaction is expected to close on or about November 30.
Why it matters
The deal converts a stream of future drug royalties into immediate cash for BioLineRx, a development-stage biotech company. Because BioLineRx retains potential commercial milestone payments under its Ayrmid Pharma licensing agreement, the transaction gives up only part of the economics tied to APHEXDA.
The transaction is a disclosed sale price of $5.6 million for a 14.4% share of future APHEXDA net sales, with no valuation comparator provided. The eventual return to the buyer depends on APHEXDA sales that have not yet occurred and are not quantified in the announcement.
The players
BioLineRx
BioLineRx is an Israeli biopharmaceutical company that licenses and develops therapies, including APHEXDA and the GLIX1 candidate in clinical trials for glioblastoma and other solid tumors.
Soleus Capital
Soleus Capital is an investment firm that acquires royalty interests in pharmaceutical and biotechnology products.
The details
BioLineRx agreed to sell its rights to certain future royalties from APHEXDA, which is FDA-approved for stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation. The company plans to use the proceeds for research and development and partial repayment of its loan with BlackRock EMEA Venture and Growth Lending, whose agreement includes a $4 million minimum cash balance requirement.
Timeline
- The royalty sale to Soleus Capital is expected to close on or about November 30.
Industry Context
Selling future royalty streams is a financing route that biotech companies use to raise capital without issuing equity, and this deal follows that pattern by monetizing a 14.4% interest in APHEXDA sales. BioLineRx keeps potential milestone payments from its Ayrmid Pharma license, which separates the royalty sale from the company's remaining commercial upside.
For readers following biotech stocks or investing in drug developers, this sale shows how a company can raise cash by giving up part of a future drug revenue stream. The practical effect on the company's finances depends on how the proceeds are used for research and loan repayment.
The takeaway
Companies with approved drugs can monetize future royalties to fund operations without diluting shareholders, but the value to the buyer depends on sales that have not yet happened. Watching the closing and how the proceeds are deployed will show whether the financing extends BioLineRx's runway.
What happens next
The royalty sale to Soleus Capital is expected to close on or about November 30.
Further reading
For related coverage of drug development and financing, see Biotech news on Wisevoter.
Source note: This article includes information reported by Becker's Hospital Review | Healthcare News & Analysis.



